Newamsterdam Pharma CO N.V. (NAMSW) — 10-Q Filings

10-Q Filings (6)

• NewAmsterdam Pharma's Q3 Loss Widens on Warrant Valuation Swings — Nov 5, 2025 Risk: high
  NewAmsterdam Pharma Co N.V. (NAMSW) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $72.005 million, up from
• NewAmsterdam Pharma's Q2 Loss Widens Amid R&D Surge — Aug 6, 2025 Risk: high
  NewAmsterdam Pharma Co N.V. reported a net loss of $36.7 million for the three months ended June 30, 2025, an increase from a net loss of $28.5 million in the p
• NewAmsterdam Pharma Q1 2025 10-Q Filed — May 8, 2025 Risk: medium
  NewAmsterdam Pharma Co N.V. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including changes in fair value of ea
• NewAmsterdam Pharma Q3 Update: Earnout & Warrant Valuation — Nov 6, 2024 Risk: medium
  NewAmsterdam Pharma Co N.V. reported its third-quarter results for the period ending September 30, 2024. The company's filing details changes in the fair value
• NewAmsterdam Pharma Files Q2 2024 10-Q — Aug 7, 2024 Risk: medium
  NewAmsterdam Pharma Co N.V. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance, including changes in the fair value of
• NewAmsterdam Pharma Files Q1 2024 10-Q Report — May 8, 2024 Risk: low
  NewAmsterdam Pharma Co N.V. (NAMSW) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Filed a 10-Q report for the period ending March 31, 2024. Repor

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX